U.S. flag An official website of the United States government
  1. Home
  2. Safety
  3. Recalls, Market Withdrawals, & Safety Alerts
  4. Aurobindo Pharma USA, Inc. Initiates Voluntary Nationwide Consumer Level Recall of 38 Lots of Ranitidine Tablets 150mg, Ranitidine Capsules 150mg, Ranitidine Capsules 300mg and Ranitidine Syrup 15mg/mL Due to the Detection of NDMA (Nitrosodimethylamine) Impurity
  1. Recalls, Market Withdrawals, & Safety Alerts

FDA ANNOUNCEMENT

Aurobindo Pharma USA, Inc. Initiates Voluntary Nationwide Consumer Level Recall of 38 Lots of Ranitidine Tablets 150mg, Ranitidine Capsules 150mg, Ranitidine Capsules 300mg and Ranitidine Syrup 15mg/mL Due to the Detection of NDMA (Nitrosodimethylamine) Impurity

Summary

Company Announcement Date:
FDA Publish Date:
Product Type:
Drugs
Reason for Announcement:
Recall Reason Description
NDMA (Nitrosodimethylamine)
Company Name:
Aurobindo Pharma USA, Inc.
Brand Name:
Brand Name(s)
Aurobindo & DG Health
Product Description:
Product Description
Ranitidine

FDA Announcement

Aurobindo Pharma USA, Inc. is conducting a voluntary recall of 1 lot of Ranitidine Tablets 150mg to the retail level and 37 lots of Ranitidine Capsules 150mg, Ranitidine Capsules 300mg and Ranitidine Syrup 15mg/mL to the consumer level due to the detection of NDMA (Nitrosodimethylamine) Impurity in the finished product. The impurity detected is N-nitrosodimethylamine (NDMA), which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probable human carcinogen as per International Agency for Research on Cancer (IARC) classification. To date, Aurobindo Pharma USA, Inc. has not received any reports of adverse events related to this recall.

Ranitidine is a competitive, reversible inhibitor of the action of histamine at the histamine H2 receptors found in gastric parietal cells. This results in decreased gastric acid secretion and gastric volume, and reduced hydrogen ion concentration. Uses are:

  • Relieves heartburn associated with acid indigestion and sour stomach.
  • Prevents heartburn associated with acid indigestion and sour stomach brought on by eating or drinking certain foods and beverages. 

Patients who prescribed or are taking Ranitidine Tablets 150mg, Ranitidine Capsules 150mg, Ranitidine Capsules 300mg and Ranitidine Syrup 15mg/mL should continue taking their medication.  Patients should contact their pharmacist or physician who can advise them about an alternative treatment prior to returning their medication.
The products subject to recall are listed below and are packaged in bottles. The product can be identified by checking the product name, manufacturer details and batch or lot number on the bottle containing these products.

Product Name NDC Batch Number Exp. Date
Ranitidine Tablets 150mg 55910-092-79 NBSB19001DA3 Feb-2021
Ranitidine Capsules 150mg 59651-144-60 RA1518001-A Jul-2020
RA1518002-A Jul-2020
59651-144-05 RA1518002-B Jul-2020
RA1518003-A Jul-2020
RA1518004-A Aug-2020
RA1518005-A Aug-2020
59651-144-60 RA1518005-B Aug-2020
RA1518006-A Aug-2020
59651-144-05 RA1518007-A Sep 2020
RA1518008-A Sep 2020
RA1518009-A Sep 2020
RA1518010-A Oct 2020
RA1518011-A Nov 2020
RA1518012-A Nov 2020
RA1518013-A Nov 2020
RA1518014-A Nov 2020
RA1518015-A Nov 2020
59651-144-60 RA1519003-A May-2021
59651-144-05 RA1519003-B May 2021
RA1519004-A May 2021
Ranitidine Capsules 300mg 59651-145-30 RA3018001-A Jul-2020
RA3018002-A Jul-2020
RA3018003-A Jul-2020
RA3018004-A Aug-2020
RA3018005-A Aug-2020
RA3018006-A Aug-2020
RA3018007-A Sep-2020
RA3018008-A Sep-2020
RA3018009-A Sep-2020
RA3018010-A Oct-2020
RA3019001-A Jan 2021
RA3019002-A Jan 2021
RA3019003-A May-2021
Ranitidine Syrup (Ranitidine Oral Solution, USP)  15 mg/mL (75 mg/5 mL) 65862-431-74 UI1519001-A May-2021
UI1519002-A May-2021
UI1519003-A May-2021
UI1519004-A May-2021

Ranitidine Tablets 150mg, Ranitidine Capsules 150mg, Ranitidine Capsules 300mg and Ranitidine Syrup 15mg/mL were distributed nationwide to Aurobindo Pharma USA, Inc. and AuroHealth wholesale and distributor customers 28 September 2018 through 19 September 2019. Qualanex, on behalf of Aurobindo Pharma USA, Inc. will be notifying its distributors and customers by phone and in writing to immediately discontinue distribution of the specific lots being recalled and to notify their sub-accounts. Aurobindo Pharma USA, Inc. is arranging for return of all recalled products to Qualanex. Instructions for returning recalled products are given in the recall letter.

Consumers with medical questions regarding this recall or to report an adverse event can contact Aurobindo Pharma USA, Inc. at:

Consumers should also contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.

Any general questions regarding the return of this product please contact Qualanex at 1-888-504-2014 or email recall@qualanex.com (live calls received 7:00 am to 4:00 pm M-F CST).

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

  • Complete and submit the report Online
  • Regular Mail or Fax: Download form or call 1- 800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.


FDA Contact Information

Consumers:
Qualanex
1-888-504-2014
recall@qualanex.com

Product Photos